September 26th 2024
The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Adalimumab targets PsO inflammation, not necessarily heart disease
July 2nd 2018Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.
Foods that trigger skin flares
June 25th 2018Diet can affect skin conditions including acne, atopic dermatitis, psoriasis and rosacea. In a review that focuses on these four conditions, plus aging, Rajani Katta, M.D., and Mary Jo Kramer, B.S., writing in Skin Therapy Letter, highlight trigger foods that should be avoided.
Calming inflammation in common skin conditions
June 7th 2018Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.